Short answer: Yes. Many contract manufacturers (CMOs) offer tranexamic acid injection that meets Indian Pharmacopoeia (IP) standards, typically as sterile fill-finish services (and some also handle API supply). To move forward, you’ll want to specify whether you need API supply, finished injectable (IP-compliant) Fill-Finish, or both, and confirm regulatory scope (India-only vs export).
Here’s what to plan and how to evaluate CMOs
What to prepare and specify
- Product scope
- Are you sourcing API only or a finished product (tranexamic acid injection IP) ready for packaging?
- Concentration and dosage form (e.g., 100 mg/mL in vials, standard presentation sizes, lyophilized vs liquid if applicable).
- IP monograph references and any additional regulatory requirements for your target market(s).
- Regulatory and quality
- Facility must be licensed for sterile injectable manufacturing (CDSCO in India) and compliant with GMP (Schedule M in India, or equivalent for other markets).
- IP-compliant finished product: sterility, endotoxin testing, pyrogen testing, particulates, container–closure integrity, stability under IP guidelines.
- Analytical methods validated for tranexamic acid (assay, impurity profile, related substances, dissolution if applicable), with stability data (ICH-compliant long-term and accelerated).
- Manufacturing capabilities you’ll need
- Sterile fill/finish capability (aseptic filling, closure integrity testing, sterilization method, container compatibility).
- Packaging and labeling that comply with regulatory requirements (lot/expiry, batch records, serialization if needed).
- Cleaning validation, process validation (aseptic process validation), method validation.
- Quality systems and documents
- Quality agreement detailing responsibilities, change control, CAPAs, deviations, recalls.
- Batch manufacturing records, COA/CoA for IP grade tranexamic acid API if applicable, raw material specifications, supplier audits.
- Stability protocol and stability data (IP storage conditions; per ICH guidelines).
- Commercial terms
- Target batch sizes, annual demand, lead times, minimum order quantities, payment terms.
- Change control, change in formulation, or supplier changes.
- Intellectual property protection and confidentiality.
What to look for in a CMO
- Regulatory track record: experience with sterile injections, IP-grade products, and successful audits by CDSCO or international agencies (FDA/EMA) if you plan to export.
- Facility qualifications: cleanroom class, sterilization validation, aseptic processing, packaging lines for vials, stability chambers.
- Quality culture: strong QA/QC, robust deviation/CAPA handling, and traceable documentation.
- Technical capabilities: validated analytical methods for tranexamic acid, impurity profiling, validated sterilization (Moist heat, autoclave, or other), endotoxin testing capability (LAL).
- Economics and supply chain: pricing tiers, scalability, raw material supply, contingency plans.
Typical contract structure and documents
- Master Service Agreement (MSA) plus a Quality Agreement.
- Technical specification sheet for Tranexamic Acid Injection IP.
- Device/packaging specs if applicable (vial size, stopper material, closure).
- Master batch records, process validation summary, sterility and endotoxin test plans.
- Stability timeline and reporting milestones.
- RFQ responses with: unit price, lead times, minimum order quantities, payment terms, and regulatory compliance statements.
Sample RFQ / inquiry content you can send
- Product: Tranexamic acid injection IP
- Formulation: sterile injectable; specify concentration, presentation, packaging
- IP compliance: confirm IP monograph compliance, sterility, endotoxin limits, related substances per IP
- Manufacturing steps: API sourcing (if applicable), sterile fill-finish, packaging, labeling
- Regulatory: CDSCO license status, cGMP compliance, previous audits
- Quality: validated analytical methods, stability data, acceptance criteria
- Capacity and timing: max monthly/annual capacity, batch sizes, lead times
- Documentation: COA, batch records, validation reports, stability data
- Terms: pricing, MOQs, payment terms, change control, recalls, IP protection
Next steps I can help with
- Draft a concise RFQ template you can send to CMOs.
- Create a vendor shortlisting checklist (mandatory vs nice-to-have criteria).
- Prepare an email/template to approach CMOs.
Questions to tailor the advice
- Do you need API supply, finished product, or both?
- Which market(s) are you targeting (India only, or export)? If export, which regulatory harmonies (US/EU/others)?
- What batch size and annual volume are you aiming for?
- Do you require serialization or track-and-trace features?
- Do you already have IP monograph references or regulatory approvals in hand?
If you’d like, tell me your target market, volume, and whether you want an RFQ draft or a ready-to-send inquiry email, and I’ll tailor it for you.